Seattle-based Omeros got a rough welcome Thursday to the stock market, losing 12.7 percent of its $10 initial public offering (IPO) price in its first day as a public company. It kept falling Friday, too. Shares of Omeros, a …
Finally, BB&T Corporation (NYSE:BBT) announced that it is going to purchase NPBC in a $1.8 billion, cash-and-stock transaction. BBT believes the National Penn Bancshares purchase will include another $100 million in …
Stock buybacks are when companies buy back their own stock, removing it from the marketplace. Stock buybacks increase the value of the remaining shares because there is now less common stock outstanding …
... stock from the most recent broker reports is 39.12 The stock increased +2.35% (+0.20) during the last days session, reaching 8.72 and roughly 0 shares were bought or sold by traders. Omeros Corporation is a …
Omeros
Today, the company is reporting that the program was essentially a bust. Omeros stock fell 40 percent on the news in after-hours trading. “We are obviously disappointed and surprised by the outcome,” Omeros CEO …
Investors in Omeros Corp saw new options become available this week, for the December 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the OMER options chain for the new …
* Files for stock shelf of up to $100 million - sec filing Source text : 1.usa.gov/1PaGHd2 Further company coverage:
Reuters11mon
The S&P 500 and Nasdaq closed at record highs Friday after buying erupted mid-morning on the heels of the December non-farm payroll report. Omeros Corporation (NASDAQ:OMER) however was unable to capture …
BOSTON (MarketWatch) -- Shares of Omeros Corp. OMER, -0.32% tumbled 18% to $10.92 after it priced a stock offering at a substantial discount. The biotech group plans to offer 2.93 million shares at $10.25 a share, which …
Omeros intends to use the net proceeds of the offering for general corporate purposes, including funding research and development expenses for its clinical OMS721 program and clinical trials, pre-clinical studies, …